Athera was a clinical stage biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs for the prevention and treatment of immunovascular disease. The Company initiated its lead program in 2005, based on innovations made at Karolinska Institutet, Sweden. The development of the antibody therapy was in part co-financed by the EU FP7 program, in the project CARDIMMUN. Athera closed down operations in 2021, after reporting of a clinical Phase 2 study.
Company Details
- Address
- Stockholm, Se
- Phone
- 46761938190
- in****@****hera.se
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- athera.se
- Keywords
- Immunovascular disease, Clinical stage development, Fully human monoclonal antibodies, Therapeutic antibodies, oxidised phospolipids, cardiovascular disease, vascular inflammation.
- HQ
- Stockholm
Athera Biotechnologies Ab Questions
Athera Biotechnologies Ab's helpline number is 46761938190
Athera Biotechnologies Ab's website is athera.se
Athera Biotechnologies Ab's LinkedIn profile is https://se.linkedin.com/company/athera-biotechnologies-ab
Athera Biotechnologies Ab's industry is
Biotechnology Research
Athera Biotechnologies Ab's top competitors are
Smartcella Holding Ab,
Bioarctic,
Alzecure Pharma,
Anocca,
Biolamina,
Nextcell Pharma Ab,
Xbrane Biopharma Ab,
Northx Biologics,
Pelago Bioscience Ab,
Sprint Bioscience.
Athera Biotechnologies Ab's support email address is info@athera.se
Athera Biotechnologies Ab's categories are Biotechnology Research
